Evidence map›Paper›PMID 21885636›Full record

GuidelineAmerican journal of respiratory and critical care medicine2011

An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.

Raed A Dweik, Peter B Boggs, Serpil C Erzurum, Charles G Irvin, Margaret W Leigh, Jon O Lundberg, Anna-Carin Olin, Alan L Plummer, D Robin Taylor, American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications

2 registry-linked trialsAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in American journal of respiratory and critical care medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,019 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,019citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01761006 terminatednot on this mapstarted 2013, after this paper: background citation

A Single-Center Exploratory Study to Evaluate FeNO Using the NIOX MINO® Device in COPD Patients Aged ≥40 Years During and Following Recovery From an Acute COPD Exacerbation

TypeobservationalSponsorWake Forest UniversityRan2013 to 2014Enrolled10ConditionsChronic Obstructive Pulmonary DiseaseArmsNIOX MINO®
NCT04885738 unknown statusnot on this mapstarted 2021, after this paper: background citation

The Value of Exhaled Nitric Oxide in Predicting Airway Eosinophilic Inflammation in Chronic Airway Inflammatory Disease

Typeobservational_patient_registrySponsorThe First Affiliated Hospital of Guangzhou Medical UniversityRan2021 to 2022Enrolled2,052ConditionsBiomarkers, Airway InflammationArmsno intervention
3 · Its place in the literature

Who cites it

1,019 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Article
  15. Article
  16. Observational
  17. Observational
  18. Article
  19. Article
  20. Review

959 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Raed A Dweik
Peter B Boggs
Serpil C Erzurum
Charles G Irvin
Margaret W Leigh
Jon O Lundberg
Anna-Carin Olin
Alan L Plummer
D Robin Taylor
American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications

Funding

Targeting pathological hyaluronan matricesP01HL103453 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C. · 2011 to 2020
$26.8M
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*U10HL109250 · NHLBI · UNIVERSITY OF VIRGINIA · PI ERZURUM, SERPIL C., GASTON, BENJAMIN · 2011 to 2016
$4.2M
NHLBI NIH HHS P01 HL103453NHLBI NIH HHS U10 HL109250
6 · The paper itself

Abstract

backgroundMeasurement of fractional nitric oxide (NO) concentration in exhaled breath (Fe(NO)) is a quantitative, noninvasive, simple, and safe method of measuring airway inflammation that provides a complementary tool to other ways of assessing airways disease, including asthma. While Fe(NO) measurement has been standardized, there is currently no reference guideline for practicing health care providers to guide them in the appropriate use and interpretation of Fe(NO) in clinical practice. PURPOSE: To develop evidence-based guidelines for the interpretation of Fe(NO) measurements that incorporate evidence that has accumulated over the past decade.

methodsWe created a multidisciplinary committee with expertise in the clinical care, clinical science, or basic science of airway disease and/or NO. The committee identified important clinical questions, synthesized the evidence, and formulated recommendations. Recommendations were developed using pragmatic systematic reviews of the literature and the GRADE approach.

resultsThe evidence related to the use of Fe(NO) measurements is reviewed and clinical practice recommendations are provided.

conclusionsIn the setting of chronic inflammatory airway disease including asthma, conventional tests such as FEV(1) reversibility or provocation tests are only indirectly associated with airway inflammation. Fe(NO) offers added advantages for patient care including, but not limited to (1) detecting of eosinophilic airway inflammation, (2) determining the likelihood of corticosteroid responsiveness, (3) monitoring of airway inflammation to determine the potential need for corticosteroid, and (4) unmasking of otherwise unsuspected nonadherence to corticosteroid therapy.

Indexed as

ExhalationAsthmaBiomarkersBreath TestsHumansLungNitric OxideBiomarkersNitric Oxide

Identifiers

PMID21885636
PMCPMC4408724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.